Gabriella Farina

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 477 citations

Medicine, Oncology, Pharmacology +14

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

Dino Amadori, Massimo Aglietta, Barbara Alessi et al. · The Lancet Oncology · 2013 · 201 citations

Medicine, Oncology, Pharmacotherapy +15

Complications of Subcutaneous Infusion Port in the General Oncology Population

C Ballarini, Mattia Intra, Andrea Pisani Ceretti et al. · Oncology · 1999 · 129 citations

Medicine, Oncology, Surgery +13

Pulmonary Artery Growth After Palliation of Congenital Heart Disease With Duct-Dependent Pulmonary Circulation

Giuseppe Santoro, Giovanbattista Capozzi, Giuseppe Caianiello et al. · Journal of the American College of Cardiology · 2009 · 118 citations

Medicine, Cardiology, Surgery +15

<i>KRAS</i> mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy

Mirko Marabese, Monica Ganzinelli, Marina Chiara Garassino et al. · Oncotarget · 2015 · 91 citations · Full text

Medicine, Oncology, Pharmacology +14